Trastuzumab deruxtecan benefit for some advanced gastric cancers

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

Tumor Treating Fields plus chemo shows OS benefit in unresectable pancreatic cancer

Making immune check point inhibitors for lung cancer cost-effective in LMICs

Abemaciclib potential therapeutic option for Kaposi sarcoma

ASCO 2025: Latest in EGFR positive NSCLC

Ecological evaluation of climate risks for cancer survivors

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma

Sacituzumab govitecan helps postpone progression in some PD-L1-positive triple-negative breast cancer patients

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

Characteristics associated with longer-term OS with NALIRIFOX regimen in metastatic pancreatic adenocarcinoma